




# Solo 2


## ENGOT-OV21

### Study of O<sup>L</sup>oparib in O<sup>V</sup>arrian Cancer

A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy



# Final Global Recruitment



--- GLOBAL Planned

— GLOBAL Randomised



# Next Steps

- ▶ **Change of the Study Primary Endpoint** : the protocol was modified to use investigator assessment of PFS as the primary endpoint and PFS confirmed by independent panel review as a sensitivity analysis.
- ▶ **Protocol amendment in submission**
- ▶ **Data cut-off date has been set to 19th Sept 2016.**